


Welcome to the COVID-19 Provider Webinar

Friday, September 1, 2023
9:00AM – 10:30AM



Questions

During today's session, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.



Resource links will be dropped into, “Chat”

Housekeeping

Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Attendees:



Today's session is being recorded. Access today's slides and archived presentations at:
[EZIZ COVID Education](#)



If you have post-webinar questions, please email leslie.amani@cdph.ca.gov

COVID-19 Vaccine Agenda: Friday, September 1, 2023

No.	Item	Speaker	Time (AM)
1	Welcome and Announcements	Leslie Amani (CDPH)	9:00 – 9:05
2	Vaccine Administration Data	Sharon Brummitt (CDPH)	9:05 – 9:10
3	Clinical Update	Caterina Liu, M.D. (CDPH)	9:10 – 9:20
4	Storage and Handling	Katherine McHugh (CDPH)	9:20 – 9:25
5	Vaccine Management	Josh Pocus (My Turn) and Claudia Aguiluz (myCAvax)	9:25 – 9:35
6	COVID-19 Vaccine Commercialization, BAP, and VFC	Claudia Aguiluz (CDPH)	9:35 – 9:45
7	Pharmacy Update	Edward Salaguinto, PharmD, RPh (CDPH)	9:45 – 9:50
8	Resources and Q&A	CDPH Subject Matter Experts	9:50 – 10:30

Thank you, California COVID-19 Vaccination Program Providers!

Announcements

Leslie Amani, CDPH



CDPH Communications Listserv Updates

- Email Blanca Corona at Blanca.Corona@cdph.ca.gov to subscribe to the COVID-19 Vaccine Listserv or to receive help with troubleshooting.
- View [archived communications](#)
- No longer receiving communications? Make sure you have marked our new email as a “**safe sender**” on your email account: ProviderCallCenter@cdph.ca.gov to prevent communications from going to your spam, junk, or other folder.
- **New BAP Listserv Coming:** Providers, MCEs, and LHDs who are subscribed to the COVID-19 vaccine Listserv will **automatically be subscribed** to our new BAP Listserv, expected to go live in mid-September. More information is forthcoming, stay tuned!



Virtual Grand Rounds

Topic: New Communicable
Disease Guidance for Schools

When: Tuesday, September 12, 2023
Time: 12PM – 1PM

Register [here](#)



Virtual Grand Rounds

EMERGING PUBLIC HEALTH ISSUES

**Virtual Grand Rounds: New
Communicable Disease Guidance for
Schools**

[Register](#)

Tuesday, September 12, 2023

12:00-1:00pm

The California Department of Public Health has published comprehensive Communicable Disease Guidance for Schools. The guidelines, created in collaboration with multiple stakeholders, will be an important resource for clinicians, educators and administrators, and parents.

Sohil Sud, M.D., a pediatrician who led the creation of these guidelines with the input of multiple stakeholders, will present the guidelines along with several team members including Sheri Coburn, MSN, Ed.D., Matt Zahn, MD and Mark Sawyer MD.

Additionally, California State Epidemiologist Erica Pan, M.D., MPH, will present updates on COVID-19 and the current status of vaccine recommendations for the fall.



Afternoon TEAch Webinar



CDPH TEAch Webinar

Save the Date
Afternoon TEAch Webinar:
"What's New with Flu, RSV, and COVID-19?"

When: Thursday, September 14, 2023 at 12PM - 1PM, PST

Topics:

- 2023 Advisory Committee on Immunization Practices (ACIP) recommendations on respiratory diseases: Influenza (flu) and Respiratory Syncytial Virus (RSV)
- Updates on COVID-19 vaccine formulation for children
- Transition of COVID-19 vaccines to the VFC Program

By the end of the webinar, attendees should be able to:

- Describe the latest ACIP flu and RSV immunization recommendations.
- Understand the new COVID-19 vaccine formulations for children.
- Understand how COVID-19 vaccines will become part of the VFC Program.
- Identify relevant patient and provider education resources.

Description: This Afternoon TEAch webinar will cover what's new with RSV and Flu, updates on the COVID-19 vaccine formulation, and the transition of COVID-19 vaccines to the Vaccines for Children (VFC) program.

When: Thursday, September 14, 2023

Time: 12PM – 1PM, PT

[Register here](#)



CDC COCA Call

Topic: Preparing for the Upcoming Respiratory Virus Season: Recommendations for Influenza, COVID-19, and RSV Vaccines for Older Adults

When: Tuesday, September 19, 2023

Time: 11AM – 12PM

No Registration needed.

Zoom meeting link to join [here](#)

During this COCA Call, CDC presenters will provide updates about the latest recommendations and clinical considerations for administering influenza, COVID-19, and RSV vaccines to adults 60 years and older and discuss resources and communication strategies that may help facilitate older adult vaccination.

[CDC Emergency Preparedness and Response Webpage](#)

Request for Photos from Providers

CDPH wants to celebrate all the LHDs and Providers who have contributed so much to the California COVID-19 Vaccination Program.

Please email any staff photos to leslie.amani@cdph.ca.gov by Friday, September 8, 2023.



Vaccine Administration Data

Sharon Brummitt, CDPH

Vaccine Administration Summary

as of August 28, 2023


89,738,261

Total Doses Administered:


8,546,251

Total Up-to-Date Recipients:

Daily Doses Administered: **Statewide**



Percent of Population Who Are Up-to-Date



Trends in Vaccine Administration*

as of August 28, 2023


Week-to-Week Trends

Highest uptake among 65+ and Under 5

Under 5 rates remain stable

Slight decrease in uptake among all other age groups

Doses Administered per 100K by Age Group, Past 4 Weeks



Doses Administered by Age Group, 4 Week Average

Under 5	5-11	12-17	18-49	50-64	65+
2,576	1,972	1,965	10,591	5,343	17,790
doses per week	doses per week	doses per week	doses per week	doses per week	doses per week

*Estimates are approximations based on comparison of vaccination data to DOF 2021 population estimates


Up-to-Date Status by Race/Ethnicity*

as of August 28, 2023

Highest uptake in Asian and White

Over half of those in each race/ethnicity group have completed their primary series but are not Up-to-Date

Race/Ethnicity: % of Population by Vaccine Status: Up To Date | Not Up To Date | No Shots



*Vaccination rate estimates for some groups, such as NHPI, may be affected by differences in how demographic data is collected by the Census and at the time of vaccination

Up-to-Date Status Among 50+ by Race/Ethnicity*


as of August 28, 2023

Intersection of Age and Race/Ethnicity

Highest uptake in 65+, White, and Asian

Up-to-Date status varies across age and race/ethnicity with wider variation within the 65+ vs 50-64

Percent of 50+ Population Who Are Up-to-Date by Age and Race/Ethnicity




*Estimates are approximations based on comparison of vaccination data to DOF 2021 population estimates

Up-to-Date Status Among 65+ by County

as of August 28, 2023

Uptake varies geographically:

- Highest rates in coastal counties
- Ranges from **18.2%-66.4%** of 65+ population



Data Summary

as of August 28, 2023

Key Metrics

89.7 million doses administered | **+36K** doses administered
21.4% Statewide Up-to-Date | **8.5 million** Up-to-Date recipients
19% difference in Up-to-Date across Race/Ethnicity groups

System Notes

- Public dashboard reflects Up-to-Date status
 - Public dashboard updated monthly
- Email cdphvaccinedatateam@cdph.ca.gov for questions and comments

Clinical Update


Caterina Liu, M.D., CDPH

BA.2.86 Variant and COVID Vaccines

- BA.2.86 is a new SARS-CoV-2 variant with a large number of mutations compared with previously detected Omicron variants.
- Limited virus samples currently available.
- Too soon to know real-world impacts on immunity. Scientists are evaluating the effectiveness of the forthcoming, updated COVID-19 vaccine.
- BA.2.86 may be more capable of causing infection in people who have previously had COVID-19 or who have received COVID-19 vaccines. CDC's current assessment is that this updated vaccine will be effective at reducing severe disease and hospitalization.

Policy Considerations for Fall 2023-2024 COVID-19 Vaccine Composition Change

Policy on COVID-19 vaccine composition change will be coordinated with FDA for regulatory action and CDC for recommendations for use





Upcoming ACIP Meeting

CDC Advisory Committee on Immunization Practices (ACIP)

Topic (Anticipated): Fall 2023 COVID-19 Vaccine

When: Tuesday, September 12, 2023

Time: 7AM, PST

[Webcast Link to Join](#)

ACIP Meeting Agenda (Not Yet Posted)

CDC 2023-2024 Influenza Guidance

Highlighted updates:

- 2023-2024 Influenza Vaccine Composition
- Egg allergy updates
 - ACIP recommends that all persons aged ≥ 6 months with egg allergy should receive influenza vaccine. Any influenza vaccine (egg based or nonegg based) that is otherwise appropriate for the recipient's age and health status can be used. Egg allergy alone necessitates no additional safety measures for influenza vaccination beyond those recommended for any recipient of any vaccine, regardless of severity of previous reaction to egg.

Influenza Vaccine Reminders

- Children under 9 years of age with a history of fewer than 2 doses of influenza vaccine are recommended to receive 2 doses this flu season.
- High-dose, adjuvanted, or recombinant influenza vaccines are **preferred** for adults ages 65 years and older.
- Influenza vaccines can be co-administered with other routine vaccines, including COVID-19 and RSV vaccines.

Influenza Resources

Influenza Vaccine ID Guide (Updated for 2023-24)

Influenza Vaccination Resources

Flu and Respiratory Disease Prevention Promotion Resources

PEDIATRIC/ADULT INFLUENZA VACCINE 2023-2024

AGE GROUP	VACCINE	MANUFACTURER	DOSE
6 MONTHS & OLDER	Fluarix® Quadrivalent	GlaxoSmithKline Biologicals	0.5 mL single-dose syringe
	Flucelvax® Quadrivalent	Seqirus	0.5 mL single-dose syringe
	Afluria® Quadrivalent	Seqirus	0.5 mL single-dose syringe
	FluLaval® Quadrivalent	GlaxoSmithKline Biologicals	0.5 mL single-dose syringe
	Fluzone® Quadrivalent	Sanofi Pasteur, Inc.	0.5 mL single-dose
	Fluzone® Quadrivalent	Sanofi Pasteur, Inc.	0.5 mL single-dose vial
3 YEARS & OLDER	Afluria® Quadrivalent	Seqirus	5.0 mL multi-dose vial*
	Flucelvax® Quadrivalent	Seqirus	5.0 mL multi-dose vial*
2-49 YEARS OLD & HEALTHY	FluMist® Quadrivalent	Medimmune Vaccines, Inc.	0.2 mL single-dose nasal sprayer
	FluBlok® Quadrivalent	Protein Sciences	0.5 mL single-dose syringe
65 YEARS & OLDER	FLUAD® Adjuvanted Quadrivalent	Seqirus	0.5 mL single-dose syringe
	Fluzone® High-Dose Quadrivalent	Sanofi Pasteur, Inc.	0.7 mL single-dose syringe

STORE ALL INFLUENZA VACCINES IN THE REFRIGERATOR.

VFC Questions:
Call 877-2Get-VFC (877-243-8832)

Children under 9 years of age with a history of fewer than 2 doses of influenza vaccine are recommended to receive 2 doses this flu season. See [CDC Website](#).

Vaccines available through the Vaccines for Children Program in 2023-24 should only be used for VFC-eligible children 18 years of age or younger.

- * Multi-dose flu vaccines, which contain thimerosal, should NOT be given to pregnant women and children under 3 years of age unless Secretary of the Health and Human Services Agency issues an exemption (CA Health & Safety Code 124172).
- Preferred vaccine product for persons 65 or older. If not available, any other age-appropriate inactivated product may be given.

California Department of Public Health | IMM-850 (8/23)

FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants

- Abrysvo (Pfizer) approved for use in pregnant individuals at 32 through 36 weeks gestational age of pregnancy to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants, birth through 6 months of age.
- Highly effective in preventing severe LRTD caused by RSV.
- ACIP workgroup reviewing; recommendations anticipated fall 2023.

Nirsevimab Clinical Guidance Now Available

- [Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices_U.S. August 25, 2023](#)
- [ACIP and AAP Recommendations for the Use of the Monoclonal Antibody Nirsevimab for the Prevention of RSV Disease_August 15, 2023](#)
- [AAP: Nirsevimab Frequently Asked Questions](#)

Updated RSV Vaccine Materials

- [CDC Healthcare Provider RSV Vaccine Page](#)
- [CDC Shared Clinical Decision-Making Guidance Flyer for RSV Vaccine](#)
- [CDC Webinar: New RSV Vaccines for Adults](#)
- [Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023](#)

Shared Clinical Decision-Making (SCDM)
RSV Vaccination for Adults 60 Years and Older

- Respiratory syncytial virus (RSV) is a cause of severe respiratory illness across the lifespan. Each year in the United States, RSV leads to approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths among adults 65 years and older.
- Adults 60 years of age and older now have the option to receive one dose of RSV vaccine based on a SCDM process between a patient and their health care provider.
- Consider multiple factors when discussing RSV vaccination with your patients. SCDM recommendations are optional and are informed by whether the patient has any risk factors for severe RSV disease; a patient's risk of exposure to RSV; a patient's preferences for RSV vaccination; and the clinical discretion of the health care provider.

Underlying medical conditions associated with increased risk for severe RSV disease include:

 Chronic lung disease (e.g., COPD and asthma)	 Chronic kidney disease	 Moderate or severe immunocompromise
 Chronic cardiovascular disease (e.g., CHF and CAD)	 Chronic liver disease	 Chronic hematologic disorders
 Chronic or progressive neurologic or neuromuscular conditions	 Diabetes Mellitus	 Any underlying condition that a provider determines might increase the risk of severe RSV disease

Other factors associated with increased risk for severe RSV disease include:

 Frailty or advanced age, as determined by the healthcare provider	 Residence in a nursing home or other long-term care facility	 Any underlying factor a provider determines might increase the risk of severe RSV disease
---	--	---

Other points to consider:

- Serious neurologic conditions, including Guillain-Barré syndrome (GBS), have been reported after RSV vaccination in clinical trials. However, it is unclear whether the vaccine caused these events.
- Persons with history of severe allergic reaction (e.g., anaphylaxis) to any component of RSV vaccine should not receive the vaccine.

Additional Information:
CDC RSV Vaccine Information: <https://www.cdc.gov/eids/eid/2023/07/23/cdc-rsv-vaccine-information.html>

MMWR Report:
<https://www.cdc.gov/mmwr/volumes/72/wr/mm7222a1.htm>

 U.S. Department of Health and Human Services
Centers for Disease Control and Prevention

Storage and Handling

Katherine McHugh, CDPH



Diluent Reminder

- Use the normal saline diluent vials for Pfizer vaccines only **once**
- You cannot use one vial of diluent to dilute multiple vials of vaccine
- Discard the diluent vial immediately after use to prevent errors
- Using a vial of diluent to dilute multiple vaccines is dangerous for patients and can lead to infection

Commercialized Moderna (Spikevax)

- Presentations
 - Ages 12+
 - Single Dose Vials. 0.5 mL injection volume.
 - Prefilled Syringes
 - Ages 6month-11years
 - Single dose vials. 0.25 mL injection volume.
- Minimum Order
 - 10 doses
- Storage
 - Long-term frozen storage or refrigerated storage for up to 30 days
- Offering returns?
 - Yes, but we are still unclear on full policy

Commercialized **Novavax**

- Presentation
 - Ages 12+: 5 dose multi-dose vials. 0.5mL injection volume.
- Minimum Order
 - 10 doses
- Storage
 - Refrigerated
- Offering returns?
 - Yes, up to 100% for opened and unopened vials

Commercialized Pfizer (Comirnaty)

- Presentations
 - 6months-4 years: Requires diluent (1.1 mL normal saline). 3 dose multi-dose vials. Yellow cap. 0.3 mL injection volume.
 - 5 years – 11 years: No diluent required. Single dose vials. Blue cap. 0.3 mL injection volume.
 - 12 years+: No diluent required. Single dose vials. Gray cap. 0.3 mL injection volume.
- Minimum Order
 - 6 months-4 years: 30 doses
 - 5 years – 11 years: 10 doses (government supplied vaccine), 100 doses private purchase
 - 12 years+: 10 doses (government supplied vaccine), 100 doses private purchase
- Storage
 - Long-term storage at ultracold temperatures, if vaccine was received at ultracold temperatures
 - Short-term storage (10 weeks) at refrigerated temperatures.
- Returns Offered?
 - Yes, but we are still unclear on full policy

Vaccine Management

Josh Pocus, My Turn, and Claudia Aguiluz, myCAvax

What's New in My Turn? – Release 42



New updates for My Turn Public and Clinic launched on
Wednesday, August 30, 2023!



Release Highlights



When scheduling vaccine appointments, patients **will be able to view:**

- ✓ The clinic card that now includes the clinic's full closing date and phone number in its description on the 'Select a Location' page
- ✓ Only the vaccine brand for the vaccine tags on the 'Select a Location' page
- ✓ An updated eligibility chart link in the attestation on the 'Screening' page
- ✓ Clinics that have the location tag matching their responses to the health insurance question on the 'Screening' page

When scheduling vaccine appointments, patients **will no longer be able to view:**

- ✓ The description of the health insurance information on the 'Select a Location' page

My Turn Public

Release Highlights



Clinic Managers and Vaccine Administrators **will be able to view:**

- ✓ An updated COVID-19 timing chart link within the attestation in the 'Appointment Details' section in the Walk-in flow and single appointment editing, as well as in the 'Patient Background' section in the VA flow
- ✓ An updated help desk email on the footer 'Communications' tab and each tab on the My Turn Clinic portal

My Turn Clinic

What's New in My Turn? – Release 42



New updates for My Turn Clinic launched on **Wednesday, August 30, 2023!**



Release Highlights



New users **will be able to view:**

- ✓ An option to enroll in My Turn by clicking the 'My Turn' tab on the myCAvax landing page
- ✓ The 'Benefits of the Platform' and 'Who Can Use it?' sections, the 'Enroll Now' button under the 'Enrollment Overview' section, the 'Enroll your organization' button under the 'My Turn Overview,' section on the 'My Turn' page
- ✓ An option to create a My Turn account and a new organization within the Digital Enrollment process
- ✓ Appropriate error messages if the information related to location, CAIR ID, or the user (CM / related role) currently exists in the system
- ✓ The option to input details related to Provider Location, Organization, Provider of Record, and Clinic Manager and validate the information they have provided
- ✓ The option to enroll in My Turn with either a new Provider location or an existing one
- ✓ An email confirmation regarding the status of their enrollment application, indicating whether it is under review, approved, or rejected



Existing myCAvax users **will be able to view:**

- ✓ A new 'My Turn Enrollment' tab on the navigation bar that will allow them to start the Digital Enrollment process for My Turn
- ✓ The 'Enroll Location' button on the 'My Turn - Enrollment' page that allows them to use an existing Provider location; the button redirects them to the 'Required Training' page within the Digital Enrollment flow

Existing myCAvax users **will be able to view:**

- ✓ The option to input details related to Provider Location, Organization, Provider of Record, and Clinic Manager and validate the information they have provided
- ✓ The 'Provider Location Information' page after checking the training attestation
- ✓ A new 'Delivery Instruction' field added to the 'Provider Location' page on the My Turn Clinic portal
- ✓ An 'Address Information' section that displays the Provider location address under the 'Provider Location Details' tab
- ✓ The 'Duplicate Found' pop-up window if the entered Provider location already exists in the system with the same IIS ID
- ✓ The 'My Turn - Enrollment' page with the 'Location Account,' 'Location Address,' 'Clinic Manager,' 'Provider of Record,' 'Status,' 'Enrollment forms,' and 'Manage Account' columns
- ✓ The applications they submitted, and the applications where they are listed as the Clinic Manager under the 'My Turn - Enrollment' page
- ✓ The 'Account Owner,' 'Status,' 'Account Record Type,' and 'Clinic Manager' details on the 'Accounts' page of the Provider location on the My Turn Digital Enrollment application
- ✓ The 'Enrollment Request Submitted' page after they complete all the steps involved in the Digital Enrollment flow

Enrolling a New My Turn Location as an Existing Clinic Manager



What's Next in myCAvax? – Release 43



New updates for LHDs / MCEs will launch on
Thursday, September 14, 2023!

Release Highlights




LHDs / MCEs will:

Location Account

- ✓ No longer be able to edit shipping address fields on program locations; updates to the shipping address fields on a location account will automatically reflect on a program location
- ✓ See the address fields populated with information from the location account instead of the program location during SGF enrollment

LHDs / MCEs



What's Next in myCAvax? – Release 43



New updates for Providers will launch on
Thursday, September 14, 2023!



Providers

Release Highlights



Providers will:

General Contact / User Updates

- ✓ Have access to certain functionalities and fields based on the new 'myCAvax - SGF Approved' and 'myCAvax - BAP Eligible' permission sets

Shipment Incident

- ✓ See updated fields on the 'New Shipment Incident' pop-up window

Provider Community Site

- ✓ See an updated landing page based on the permission sets enabled
- ✓ See orders on the 'Vaccine Orders' page based on the program selected from the 'Program Selected' dropdown
- ✓ See the 'Program Selected' dropdown on multiple pages; they will see programs in the dropdown based on the permission sets enabled
- ✓ See the COVID-19 / SGF 'Shipment Incidents' page based on the program selected from the 'Program Selected' dropdown
- ✓ See the COVID-19 / SGF 'Dashboard' page based on the program selected from the 'Program Selected' dropdown
- ✓ See information icons with messages on SGF functionalities that are launching soon
- ✓ No longer see the 'Open Transfer Orders' pop-up window on the landing page

Vaccine Ordering – Provider

- ✓ See the COVID-19 / SGF 'Vaccine Order Request' page based on the program selected from the 'Program Selected' dropdown
- ✓ Be able to place vaccine order requests for SGF flu vaccine on the 'State General Fund - Vaccine Order Request' page
- ✓ Receive email notifications when their vaccine order request has been rejected or progressed to 'Fulfillment Pending'
- ✓ Receive a reminder email for an expiring COVID-19 or Outbreak draft order four days after the order creation date
- ✓ Have their draft orders deleted seven days after the order creation date; they will also receive a confirmation email for the same
- ✓ Be directed to the appropriate 'Vaccine Order Request' page when they click the 'Submit Order' button on a draft order

Bridge Access Program Enrollment

- ✓ Receive the 'myCAvax - BAP Eligible' permission set while enrolling into BAP if they do not already have the 'myCAvax - COVID' permission set

Location Account

- ✓ Have their location account's sub-status updated to 'On-Hold' and the 'Reason for On-Hold' field updated with the 'Provider Account Changes' value when the shipping address fields are updated

myCAvax – Known Issues – *Updated 8/23*



Known Issues

Incorrect Program Listed on Vaccine Orders

- ✓ We corrected an issue in which any order created by an LHD was showing the wrong Program. We also corrected the historical data.

Incorrect Primary Vaccine Coordinator Listed on the Community's 'Locations' tab

- ✓ We are working to correct an issue in which old Primary Vaccine Coordinators are displayed on the 'Locations' tab under some circumstances.



Workaround / Next Steps

- ✓ Fixed: 8/17

- ✓ Estimated Fix: 9/14

U.S. Government COVID-19 Vaccine Program Closeout Activities



Accept/ reject all transfers

- ✓ Contact the Provider Call Center if assistance is needed closing transfers with retired products.



Close all Vaccine Marketplace posts

- ✓ All open Vaccine Marketplace postings should be closed.

These activities should be completed as soon as possible.



File waste reports for appropriate vaccine

- ✓ If expired or wasted, file a waste report asap. Once deauthorized, remove vaccine from storage and file a waste report in myCAvax.



Continue to administer vaccine on-hand

- ✓ Continue to support vaccine administration and manage your vaccine inventory in myCAvax until deauthorization.



Prepare for vaccine demand post-program closeout

- ✓ Prepare to purchase COVID-19 vaccine post-program closeout.




What to expect approaching deauthorization

- ✓ All COVID-19 order processing will stop today, Friday, September 1, 2023.



U.S. Government COVID-19 Program Closeout Timeline



COVID-19 Vaccine Timeline Change



In anticipation of ACIP's meeting the week of September 11th, and the authorization of new products, CDPH has moved up timelines for the closeout of the current COVID-19 program.

Therefore, the last orders for current COVID-19 products need to be submitted by **Friday, September 1, 2023, at 3:00 PM PT** and no further orders will be accepted after this deadline.

Providers should only place orders if they have an urgent need for COVID-19 products. CDPH anticipates most Providers will not need to place orders.

All Providers should follow the steps listed in [this communication](#) to complete COVID-19 vaccine product closeout activities in myCAvax.

COVID-19 Vaccine Timeline Change



COVID-19 to BAP Program Cadence Calendar

California COVID19 Vaccination Program (Providers/LHDs)

Monday	Tuesday	Wednesday	Thursday	Friday
August 28	29	30	31	September 1
				Provider Order (submit by 3PM)
4	5	6	7	8
	LHD Approval by 10AM			
	CDPH Transmits Final orders to TPR			
		TPR deliveries		
11	12	13	14	15
FDA Meeting (TBD)	ACIP Meeting			






To streamline communication, CDPH is retiring the bi-weekly myCAvax and My Turn Office Hours. Our subject matter experts will continue to share timely updates and demos at the Tuesday LHJ Vaccination Coordination webinar and Friday Provider webinar.

The final Monday Office Hours will take place on **Monday, September 18, 2023**, from **12:00 PM – 1:00, PM PT**. (The **Monday, September 4, 2023**, webinar has been cancelled in observation of Labor Day.)

If you have not registered before and would like to attend, please register [here](#).


Slide Icon Key

Icon	Meaning
	This is to label slides that are referencing upcoming or existing functionality and how to use it in the system.
	This is to label slides that include important system reminders.
	This is to label slides that include tips and best practices to improve your system experience.

COVID-19 Vaccine Commercialization BAP and VFC

Claudia Aguiluz, CDPH

Post Sunset of the Federal COVID-19 Vaccination Program: Vaccine ordering will follow more traditional pathways for purchasing vaccines



*Federally Qualified Health Centers/Rural Health Centers

Bridge Access Program Updates for Providers



To minimize the time between the authorization of new products and ordering availability, CDC has compressed timelines for the addition of newly approved products to federal contracts, and vaccine availability soon after products are authorized/approved by FDA and recommended by ACIP.

Providers selected to participate in the Bridge Access Program will receive enrollment instructions early next week. NOTE: Providers that are not selected will not receive instructions.

VFC Program Updates for Providers



Providers participating in the VFC Program will receive a communication next week with information regarding product availability and ordering of pediatric COVID-19 vaccine doses through VFC.

All 3 brands of COVID-19 vaccines will be made available through VFC's routine vaccine order form. No prebooking will be required.

Commercial Purchase Information: Moderna

- Customers can order through their distributors or directly with Moderna
 - Moderna has signed with the major group purchasing organizations (GPOs) and with all major distributors, such as McKesson, Cardinal, AmeriSource-Bergen, etc.
 - Customers may order directly with Moderna at www.modernadirect.com.
 - The Moderna Care Team may be reached at: 1-866-MODERNA / 1-866-663-3762
- Pre-booking is not necessary but helps with the management of demand and production on the manufacturer side. On the provider side, it may prioritize shipping, and access to limited supply of packaging not available on the CDC Contract (pre-filled syringes)

Anticipated presentations (pending FDA approval)

Ages 6 months to 11 years:

- single-dose vial of .25ml




Ages 12+:

- single-dose vials of .5 ml
- pre-filled syringes of .5 ml (box of 10)*
- pre-filled syringes of .5 ml (blister pack of 10)*

* May not be available in the CDC contract


Commercial Purchase Information: Pfizer

- Providers may work with their wholesalers prior to and post launch of approved products
- May order directly with Pfizer for minimum quantity after commercial availability
- Customers may order directly at <https://primecontracts.pfizer.com/>
- The Pfizer Customer Service team may be reached at 1-800-666-7248.
- Product will ship direct from Pfizer at ultra-low temperature (ULT). Upon receipt, may storage at ULT or at 2-8 °C (shelf life of the product anticipated to be 10 weeks when stored at 2-8 °C).

Anticipated Presentations		For 12 Years of Age and Older (30 mcg)		For 5 Through 11 Years of Age (10 mcg)		For 6 Months Through 4 Years of Age (3 mcg)
	NDC 00069-2362-10		NDC 59267-4331-02		NDC 59267-4315-02	
	Single-dose vial and limited quantities of prefilled syringe [‡]		Single-dose vial		Multi-dose vial (3 doses) - dilution required	
	Minimum order: 100 doses (10x 10-vial box)		Minimum order: 10 doses (1x 10-vial box)		Minimum order: 30 doses (3x 10-vial box)	

Commercial Purchase Information: Novavax

- Currently working on a Commercialization Information packet for providers.
- Novavax will work with major distributors for providers to order as needed. **Novavax will not ship directly.**
- Providers can order through their preferred group purchasing organizations or distributors.
- Product purchasing information may be directed to Novavax CA Regional Business Director Nidal Naser at nnaser@novavax.com



Anticipated Products

- Anticipate 12+ age indication pending FDA authorization
- 5 dose vial
- Minimum order: 10 doses (2 vials)
- 0.5ml dose for all authorized indications
- Standard refrigeration
- NDC : 80631-0105-02 on box
- 80631-105-01 is on the 5-dose vial

Pharmacy Updates

Edward Salaguinto, PharmD, RPh, CDPH



Pharmacy COVID-19 Legislation

- Bill Status - AB-1286 Pharmacy. (ca.gov)
 - This bill would additionally authorize a pharmacy technician under the direct supervision and control of a pharmacist to administer influenza and COVID-19 vaccines.
- Bill Status - AB-1341 Public health: Oral therapeutics. (ca.gov)
 - This bill, until January 1, 2025, would authorize a pharmacist to furnish COVID-19 oral therapeutics, as defined, following a positive test for SARS-CoV-2, the virus that causes COVID-19, as specified.
 - This act is an urgency statute necessary for the immediate preservation of the public peace, health, or safety and shall go into immediate effect when signed by the governor.



Bridge Access Program (BAP) and Pharmacy

- **CDC will establish contracts with pharmacies to enable them to continue offering COVID-19 vaccines and with no out-of-pocket costs to uninsured individuals**
 - Walgreens – Still in contract negotiations. More information to come.
 - CVS – Still in contract negotiations. More information to come.
 - Requested all California locations to be included (locations subject to CDC approval).
 - eTrueNorth – Still in contract negotiations.
 - Pharmacy Interest Flyer with QR Code
 - Pharmacy Interest Contact Page

Q: When do we expect the contract negotiations to be finalized for pharmacy?

A: UPDATE!! CDC's goal - contracts between CDC and pharmacies finalized and ready to launch at the same time with the public health component in September. CDC is accelerating their timeline from a previously stated date of mid-October.

Q: Will pharmacies need separate storage for BAP doses?

A: No. Bridge Access Program pharmacy component will have the reimbursement model. No separate storage will be necessary.


eTrueNorth Pharmacy Interest Flyer

Bridge Access Program


**Sign up with eTrueNorth
to expand access to
COVID-19 vaccine services
in your community**

Through the Bridge Access Program, pharmacies enrolled with eTrueNorth can receive reimbursement for administering no-cost COVID-19 vaccines to uninsured and underinsured adults.


By participating, you can:



Receive **reimbursement** for vaccine administration of **commercially procured COVID-19 vaccines**.




Help **expand access to the underserved** members of your community.



Join eTrueNorth's **nationwide network** of pharmacies and be the first to hear about **new clinical opportunities**.


eTrueNorth makes participation easy by providing a secure online platform for convenient patient sign-up and facilitating reimbursement.

To register your interest, please visit: www.etruenorth.com/connect 

Those who register interest will have the first opportunity to apply for the Bridge Access Program when applications open.

The Bridge Access Program is funded by the U.S. Department of Health and Human Services.



All pharmacy applications are subject to approval by HHS.



eTrueNorth

is a U.S.-based healthcare technology company that enables retail pharmacies to expand their offerings and provide pharmacy-based testing and other clinical programs.


eTrueNorth is a proud member of:





eTrueNorth Pharmacy Bridge Access Program Connect

Complete this form for general inquiries or to indicate interest in the Bridge Access Program.



The screenshot shows the eTrueNorth Connect form. At the top, the eTrueNorth logo is on the left, and navigation links for 'For Health Plans', 'For Public Health', 'For Pharmacies', and a 'Connect' button are on the right. The form title 'Complete this form for general inquiries or to indicate interest in the Bridge Access Program.' is in yellow. The form fields are arranged in two columns: 'First name *', 'Last name *', 'Organization *', 'Title', 'Email *', and a dropdown for 'Which best describes you / your organization? *'. A checkbox for 'I'm interested in participating in the Bridge Access Program.' is on the left, and a 'Connect' button is on the right. At the bottom, contact information for media/PR is provided.

eTrueNorth For Health Plans For Public Health For Pharmacies **Connect**

Complete this form for general inquiries or to indicate interest in the Bridge Access Program.

First name *
First name

Last name *
Last name

Organization *
Organization

Title

Email *
Email

Which best describes you / your organization? *
- Select -

☐ **I'm interested in participating in the Bridge Access Program.**

Connect

Media/PR contact
media@etruenorth.com
800-208-4194 x719

Resources

Leslie Amani, CDPH

COVID-19 Vaccine Support

Type of Support

Description

Updated 8.28.23



Provider Call Center

The Provider Call Center for Providers and Local Health Departments is dedicated to medical providers in California and their COVID-19 response, specifically addressing questions about State program requirements, enrollment, and vaccine distribution, including the Vaccine Marketplace.


- Email: providercallcenter@cdph.ca.gov
- Phone: (833) 502-1245, Monday through Friday from 8AM–5PM



Enrollment Support

For enrollment support:

- Email: myCAvaxinfo@cdph.ca.gov




myCAvax Help Desk

Dedicated staff provide up-to-date information and technical support on the myCAvax system.

- Email: myCAvax.HD@cdph.ca.gov
- Phone: (833)-502-1245, option 3, Monday through Friday 8AM–6PM

For training opportunities: <https://eziz.org/covid/education/>




My Turn Clinic Help Desk

For **onboarding support** (those in the process of onboarding): myturnonboarding@cdph.ca.gov

For **technical support** with My Turn Clinic for COVID-19 and flu vaccines: mail to: MyTurn.Clinic.HD@cdph.ca.gov or (833) 502-1245, option 4: Monday through Friday 8AM–6PM

For job aids, demos, and training opportunities: flu at <https://eziz.org/covid/myturn/flu/> and COVID at <https://eziz.org/covid/myturn/>



Archived Communications

For archived communications from the COVID-19 Provider Call Center about the California COVID-19 Vaccination Program visit

- Website: [EZIZ Archived Communications](#)

COVID-19 Therapeutics Resources

Type of Support


Description

Updated 8.31.23



Clinical Guidance

As of August 31, the COVID-19 Therapeutics Warmline: **1-866-268-4322 (866-COVID-CA)** is no longer staffed for provider COVID-19 Therapeutics questions. For general question Therapeutics questions, please email: COVIDRxProviders@cdph.ca.gov



General Information

[CDPH COVID-19 Treatments Webpage](#) (provides general information for healthcare providers, allocations, distribution and ordering, drug facts sheets, and additional resources)

[CDPH COVID-19 Treatments Job Aid](#) (questions and answers for the public on COVID-19 therapeutics)

[COVID-19 Therapeutics Best Practices Checklist](#) (testing, prescribing, dispensing, and more)

[Frequently Asked Questions document](#) for clinics, providers, and pharmacists



Alert: Provider Warmline has been turned off as of Thursday, August 31, 2023.



Locating Resources

Finding Providers and Test-to-Treat Sites

- [COVID-19 Therapeutics Locator](#) (arcgis.com)
- [Test-to-Treat](#) (hhs.gov)



[LHI Therapeutics SharePoint](#)

Primary source for recorded webinars, slides, datasets and HPoP reporting information. (For access, email JEOCuser54@cdph.ca.gov)

- [Therapeutic Weekly Webinar Files](#) (Meeting Presentations, Recordings, & Q&A)
- [Therapeutic Weekly Email Update](#) files (SharePoint)
- [CDPH Therapeutics HPoP Account Verification & Reporting](#) information



Questions

For general CDPH Therapeutics questions, please email COVIDRxProviders@cdph.ca.gov

For ordering, program inquiries, signing up new HPoP Accounts: please e-mail CDPHTherapeutics@cdph.ca.gov

Stay informed!

Provider Resources on eziz.org/covid

Frequent Content Updates:

- Alerts
- Program Enrollment
- My Turn Onboarding
- Reporting Requirements
- Patient Resources
- Archived Communications
- Education & Support Materials
- More to explore!

Vaccinate ALL 58 California COVID-19 Vaccination Program ENHANCED BY Google

Program Updates
Program Enrollment
My Turn
Vaccine Management
Vaccine Administration
Reporting Requirements
Archived Communications
Patient Resources

Provider Call Center
Contact us for questions about vaccine orders, account updates, help with accessing documents, and more.
Phone: (833) 502-1245
Hours: Mon-Fri, 8AM-5PM
Email: Program Info, myCvax Technical Support, MyTurn Technical Support

My Turn Clinic Translation Line:
(833) 980-3933
Mon-Fri: 8AM-5PM

Vaccines
Manufacturer Contacts

Updates for Providers
FAQs | Provider Webinars | Crucial Conversations | Training Calendar

Alerts:
COVID-19 Vaccine Commercialization Resources

- COVID-19 Vaccine Commercialization FAQs Updated 8/28
- Commercialization at a Glance: Provider Transition Guide Updated 8/31
- U.S. Dept of Health and Human Services (HHS) COVID-19 Commercialization 7/13
- CDC Bridge Access Program Guide 7/13

Vaccine Updates

- August and September COVID-19 Vaccine Expiration Dates 8/4
- Shelf-Life Extension for Moderna COVID-19 Lots 8/3

Clinical Job Aids

- COVID-19 Vaccine Products Guide, Updated 8/4
- COVID-19 Vaccination Schedule (Timing Guide), Updated 6/9
- Calendario de la Vacuna COVID-19 (Spanish Timing Guide), Updated 5/15
- Moderna Vaccine 6 Months - 5 Years: When to Use Blue or Pink Cap, 5/10

Provider Operations

- COVID-19 Provider Operations Manual (POM), Updated 6/13
- Provider Startup Worksheet, Updated 5/8

Featured Resources
Now Enrolling Providers of Pediatric Services

- Find Information on How to Enroll
- Welcome VFC Providers | VFC vs. COVID Programs

Promoting Bivalent Vaccine:

- Stay Up to Date with COVID-19 Vaccines (CDC website)
- "I got my updated COVID-19 booster" stickers

Tools to Avoid Vaccine Mix-Ups:

- Vaccine Administration Checklist
- Preventing Administration Errors
- Coadministration Tips | Preteens

Vaccine Management:

- Ordering Vaccines | Ordering & Distribution Cadence
- Receiving Small Orders from Third Party Redistribution (TPR)
- Vaccine Management Checklist
- Reporting Doses Spoiled, Expired, or Wasted (including Moderna booster doses)
- Download the Ancillary Kit Configuration Tool (helps calculate number of items to pack for number of doses being redistributed)
- Pfizer Trainings
- myCvax Roadmap

Vaccination Guidance:

COVID-19 Vaccine Provider FAQs

- Answers to provider questions
- Updated weekly: last updated 8/31/2023
- Currently in its 131st iteration!

1.2 Q: Where can Providers find best practice strategies to effectively integrate pediatric COVID-19 vaccination into clinics and clinical talking points for recommending COVID-19 vaccines for children?

A: Providers may access a 1-page Pediatric COVID-19 Checklist [here](#) and a list of **updated** clinical talking points for recommending COVID-19 vaccination for children from this [Clinical Talking Points for Providers of Pediatric Services job aid](#).


California COVID-19 Vaccination Program Provider FAQs v.131.1_8.31.23 1

California COVID-19 Vaccination Program Provider FAQs
For Prospective, Newly Enrolled, and Current California COVID-19 Vaccine Providers.
Providers may also visit [California COVID-19 Vaccination Program](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

Contents


New and Updated FAQs	2
Pediatric Providers	2
Vaccine Program Management.....	2
Provider Enrollment	3
Ordering	4
Distribution/Redistribution	4
Vaccine Administration	4
Vaccine Storage & Handling	8
Reporting.....	9
Billing & Reimbursement	10
Communication Resources.....	10

 Vaccinate ALL 58

Commercialization at a Glance: Provider Transition Guide*

Commercialization at a Glance: Provider Transition Guide

California COVID-19 Vaccination Program



Commercialization is the transition of COVID-19 medical countermeasures—vaccines, treatments, and test kits—previously purchased by the U.S. Government (USG) to established pathways of procurement, distribution, and payment by both public and private payers. This guide summarizes the [HHS Commercialization Transition Guide](#), [HHS Bridge Access Program Fact Sheet](#), and CDPH guidance as the USG prepares to stop distributing COVID-19 vaccines and vaccines transition to the commercial market. Updated topics highlighted below. Sections include:

- Fall Transition Timeline
- Sunsetting of the Federal COVID-19 Vaccination Program
- Commercialization of COVID-19 Vaccines
- Anticipated Vaccination Schedule for the Fall

Topic	Guidance	Effective Date																		
Section 1	Fall Transition Timeline																			
	<table><thead><tr><th>Projected Timeline (All subject to change)</th><th>Action/Event</th></tr></thead><tbody><tr><td>Present – 08/03/2023</td><td>Vaccines ordered from USG on a continuing basis</td></tr><tr><td>06/15/2023</td><td>VRBPAC meeting held, committee recommended updated fall vaccine composition</td></tr><tr><td>06/16/2023</td><td>FDA statement on XBB.1.5 as recommended fall vaccine composition</td></tr><tr><td>08/03/2023</td><td>Vaccine thresholds for partners will be set to 0 in anticipation of decreased demand Note: Jurisdictions, Federal agencies, and other partners may make out of cycle requests for vaccines from USG if needed</td></tr><tr><td>TBD (expected in mid to late September)</td><td>FDA decisions and amendments to Emergency Use Authorizations (EUs) / Biologics License Applications (BLAs)</td></tr><tr><td>TBD (concurrent with FDA decision)</td><td>USG discontinues distribution of current COVID-19 vaccine composition</td></tr><tr><td>TBD (pending FDA decision)</td><td>Advisory Committee on Immunization Practices (ACIP) discussion on COVID-19 epidemiology and vaccine effectiveness and CDC recommendation</td></tr><tr><td>TBD (pending FDA decision, CDC recommendation, and manufacturer readiness)</td><td>Fall vaccine availability for administration begins across all age groups with traditional pathways for procurement, distribution, and payment</td></tr></tbody></table>	Projected Timeline (All subject to change)	Action/Event	Present – 08/03/2023	Vaccines ordered from USG on a continuing basis	06/15/2023	VRBPAC meeting held, committee recommended updated fall vaccine composition	06/16/2023	FDA statement on XBB.1.5 as recommended fall vaccine composition	08/03/2023	Vaccine thresholds for partners will be set to 0 in anticipation of decreased demand Note: Jurisdictions, Federal agencies, and other partners may make out of cycle requests for vaccines from USG if needed	TBD (expected in mid to late September)	FDA decisions and amendments to Emergency Use Authorizations (EUs) / Biologics License Applications (BLAs)	TBD (concurrent with FDA decision)	USG discontinues distribution of current COVID-19 vaccine composition	TBD (pending FDA decision)	Advisory Committee on Immunization Practices (ACIP) discussion on COVID-19 epidemiology and vaccine effectiveness and CDC recommendation	TBD (pending FDA decision, CDC recommendation, and manufacturer readiness)	Fall vaccine availability for administration begins across all age groups with traditional pathways for procurement, distribution, and payment	
Projected Timeline (All subject to change)	Action/Event																			
Present – 08/03/2023	Vaccines ordered from USG on a continuing basis																			
06/15/2023	VRBPAC meeting held, committee recommended updated fall vaccine composition																			
06/16/2023	FDA statement on XBB.1.5 as recommended fall vaccine composition																			
08/03/2023	Vaccine thresholds for partners will be set to 0 in anticipation of decreased demand Note: Jurisdictions, Federal agencies, and other partners may make out of cycle requests for vaccines from USG if needed																			
TBD (expected in mid to late September)	FDA decisions and amendments to Emergency Use Authorizations (EUs) / Biologics License Applications (BLAs)																			
TBD (concurrent with FDA decision)	USG discontinues distribution of current COVID-19 vaccine composition																			
TBD (pending FDA decision)	Advisory Committee on Immunization Practices (ACIP) discussion on COVID-19 epidemiology and vaccine effectiveness and CDC recommendation																			
TBD (pending FDA decision, CDC recommendation, and manufacturer readiness)	Fall vaccine availability for administration begins across all age groups with traditional pathways for procurement, distribution, and payment																			

California Department of Public Health, IZ Branch

1

IMM-1467 (8/22/23)

CDPH has created a multi-page “Commercialization Provider Transition Guide”.

The current information can be found on EZIZ COVID using this link:

[Commercialization at a Glance: Provider Transition Guide](#)

*Please note: Updates will be added to this document as CDPH receives information. Updated topics will be highlighted in **yellow**.

CDPH Provider Webinars and Trainings

Week of September 4, 2023

	Monday 8/28	Tuesday 8/29	Wednesday 8/30	Thursday 8/31	Friday 9/1
Live Webinars and Training	<i>Holiday</i>				COVID-19 Weekly Provider Webinar Series 9:00 am – 10:30 am
View On Demand	<ul style="list-style-type: none"> Intro to My Turn Onboarding (v. 1/4/22) Latest Features in My Turn (Requires My Turn Login) CDPH Weekly Provider Webinars Archived Recordings and Slides 		<ul style="list-style-type: none"> myCAvax Release Notes for LHJs and CDPH Users (Requires myCAvax Login) Latest Features in myCAvax for Providers (Requires myCAvax Login) COVID-19 Crucial Conversations Archived Webinars and Slides 		<ul style="list-style-type: none"> Moderna COVID-19 Vaccine Resources for Providers CDC COVID-19 Vaccine Webinar Series California Immunization Coalition COVID Conversation Series AIM Vaccine Confidence Toolkit Webinar Series
Help	Help Desk myCAvax Help Desk Email: mycavax.hd@cdph.ca.gov My Turn Help Desk Email: myturn.clinic.hd@cdph.ca.gov My Turn Onboarding Email: myturnonboarding@cdph.ca.gov		General CDPH Provider Call Center: 1-833-502-1245, 8am-5pm, Mon-Fri Email: providercallcenter@cdph.ca.gov Vaccines: COVID-19 Vaccines Therapeutics: COVID-19 Therapeutics		Mpox Email: stdcb@cdph.ca.gov General Website: Mpox Website Vaccines: Mpox Vaccines Website

Questions

During today's session, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.



Resource links will be dropped into, “Chat”

Upcoming Opportunities



Monday

My Turn and myCAvax Office Hours

Next session: Monday, September 18, 12PM-1PM

Friday

Provider Consolidated Webinar

Next session: Friday, September 8, 9AM-10:30AM

